IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome
NCT03175978
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
2
Enrollment
INDUSTRY
Sponsor class
Stopped
Funding
Conditions
Myelodysplastic Syndromes
Leukemia, Myelomonocytic, Chronic
Anemia, Refractory, With Excess of Blasts
Interventions
DRUG:
IGF/MTX
Sponsor
IGF Oncology, LLC